Key points are not available for this paper at this time.
Acute generalized exanthematous pustulosis (AGEP) is a severe cutaneous drug reaction that typically resolves rapidly following withdrawal of the offending drug and administration of systemic corticosteroids. Infliximab, a biologic agent that inhibits TNF-α, is widely used in the treatment of various inflammatory diseases. Individuals with specific genetic risk factors may be more susceptible to severe drug-induced cutaneous reactions. Here, we report the first case of successful infliximab treatment in a pregnant woman with IL17A and IL36RN mutations who developed severe AGEP after 24 days of hydroxychloroquine use and failed to respond to conventional therapy.
Jiang et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: